Table 1.
Baseline characteristics
| All (N=342) | Continued FSL-FGM (n=260) | Stopped FSL-FGM (n=82) | |
| Male gender, n (%) | 178 (52.0) | 140 (53.8) | 38 (46.3) |
| Age, years | 48.0 (15.6) | 47.7 (15.8) | 49.0 (15.1) |
| HbA1c, mmol/mol | 61.2 (12.9) | 62.1 (13.3) | 58.2 (11.4)* |
| HbA1c, % | 7.8 (1.2) | 7.8 (1.2) | 7.5 (1.0)* |
| Type of diabetes, n (%) | |||
| Type 1 diabetes | 272 (79.5) | 214 (82.3) | 58 (70.7) |
| Type 2 diabetes | 45 (13.2) | 30 (11.5) | 15 (18.3) |
| Latent autoimmune diabetes in adults (LADA) | 16 (4.7) | 10 (3.8) | 6 (7.3) |
| Maturity-onset diabetes of the young (MODY) | 2 (0.6) | 1 (0.4) | 1 (1.2) |
| Other forms of diabetes | 7 (2.0) | 5 (1.9) | 2 (2.4) |
| Complications, n (%) | |||
| Microvascular complications | 121 (35.4) | 89 (34.2) | 32 (39.0) |
| Neuropathy | 71 (20.8)† | 52 (20.0) | 19 (23.2) |
| Albuminuria | 62 (18.1) | 47 (18.1) | 15 (18.3) |
| Retinopathy | 72 (21.1) | 50 (19.2) | 22 (26.8) |
| Macrovascular complications | 50 (14.6) | 38 (14.6) | 12 (14.6) |
Data are presented as number (%) or mean (SD).
*P<0.05.
†Data available for 108 persons (80 persons who continued and 28 who stopped FSL-FGM).
FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c.